

Palle Bekker Jeppesen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2241483/publications.pdf>

Version: 2024-02-01

138
papers

8,759
citations

50244

46
h-index

43868

91
g-index

139
all docs

139
docs citations

139
times ranked

3565
citing authors

#	ARTICLE	IF	CITATIONS
1	Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 896-904.	1.3	24
2	Impact on caregivers of adult patients receiving parenteral support for short-bowel syndrome with intestinal failure: A multinational, cross-sectional survey. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 905-914.	1.3	14
3	Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 923-935.	1.3	6
4	A multi-national survey of experience and attitudes towards commencing home parenteral nutrition for patients with advanced cancer. <i>Clinical Nutrition ESPEN</i> , 2022, 47, 246-251.	0.5	5
5	Discovery of Urinary Biomarkers of Spinach Consumption Using Untargeted LC-MS Metabolomics in a Human Intervention Trial. <i>Molecular Nutrition and Food Research</i> , 2022, 66, e2100260.	1.5	2
6	Impact of intestinal failure and parenteral support on adult patients with short-bowel syndrome: A multinational, noninterventional, cross-sectional survey. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 1650-1659.	1.3	9
7	Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, 46, 1639-1649.	1.3	9
8	Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2022, , .	1.3	5
9	Drug use in patients with short bowel syndrome and intestinal failure. <i>Danish Medical Journal</i> , 2022, 69, .	0.5	0
10	Survival in patients initiating home parenteral support due to nonmalignant short bowel syndrome compared with background population. <i>Clinical Nutrition ESPEN</i> , 2022, 50, 170-177.	0.5	5
11	High Parenteral Support Volume Is Associated With Reduced Quality of Life Determined by the Short-Bowel Syndrome Quality of Life Scale in Nonmalignant Intestinal Failure Patients. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, 45, 926-932.	1.3	20
12	GLP-1 and Intestinal Diseases. <i>Biomedicines</i> , 2021, 9, 383.	1.4	20
13	Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000604.	1.1	8
14	Renal function in patients with intestinal failure receiving home parenteral support. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, , .	1.3	2
15	Characteristics of adult patients with chronic intestinal failure due to short bowel syndrome: An international multicenter survey. <i>Clinical Nutrition ESPEN</i> , 2021, 45, 433-441.	0.5	21
16	ESPEN practical guideline: Clinical nutrition in chronic intestinal failure. <i>Clinical Nutrition</i> , 2021, 40, 5196-5220.	2.3	74
17	Bovine Milk-Derived Emulsifiers Increase Triglyceride Absorption in Newborn Formula-Fed Pigs. <i>Nutrients</i> , 2021, 13, 410.	1.7	8
18	Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 44, 119-128.	1.3	38

#	ARTICLE	IF	CITATIONS
19	Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series. <i>Clinical Nutrition</i> , 2020, 39, 1774-1777.	2.3	19
20	Differences in methodology impact estimates of survival and dependence on home parenteral support of patients with nonmalignant short bowel syndrome. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 161-169.	2.2	11
21	Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 44, 697-702.	1.3	26
22	Repeated Metabolic Balance Studies in Patients With Short Bowel Syndrome. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 44, 677-687.	1.3	4
23	Citrulline correlations in short bowel syndrome—intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study. <i>Clinical Nutrition</i> , 2020, 39, 2479-2486.	2.3	14
24	Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 44, 1535-1544.	1.3	24
25	Hospitalizations in Patients With Nonmalignant Short-Bowel Syndrome Receiving Home Parenteral Support. <i>Nutrition in Clinical Practice</i> , 2020, 35, 894-902.	1.1	10
26	Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482090576.	1.4	28
27	The Long Road to the Development of Effective Therapies for the Short Gut Syndrome: A Personal Perspective. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2717-2735.	1.1	26
28	Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial. <i>EBioMedicine</i> , 2019, 46, 444-451.	2.7	19
29	Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum. <i>Journal of Parenteral and Enteral Nutrition</i> , 2019, 43, 891-898.	1.3	33
30	Su2010—Mortality and Outcomes in Patients with Non-Malignant Short Bowel Syndrome Receiving Home Parenteral Support. <i>Gastroenterology</i> , 2019, 156, S-689.	0.6	1
31	Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 354-363.	3.7	52
32	The effect of glucagon-like peptide-1 and glucagon-like peptide-2 on microcirculation: A systematic review. <i>Microcirculation</i> , 2019, 26, e12367.	1.0	10
33	Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Open-Label Pilot Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2018, 42, 112-121.	1.3	48
34	Home Parenteral Nutrition in Adult Patients With Chronic Intestinal Failure: Catheter-Related Complications Over 4 Decades at the Main Danish Tertiary Referral Center. <i>Journal of Parenteral and Enteral Nutrition</i> , 2018, 42, 95-103.	1.3	36
35	Catheter-Related Bloodstream Infections in Adults Receiving Home Parenteral Nutrition: Substantial Differences in Incidence Comparing a Strict Microbiological to a Clinically Based Diagnosis. <i>Journal of Parenteral and Enteral Nutrition</i> , 2018, 42, 393-402.	1.3	29
36	Minimal Enteral Nutrition to Improve Adaptation After Intestinal Resection in Piglets and Infants. <i>Journal of Parenteral and Enteral Nutrition</i> , 2018, 42, 446-454.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Fasting and Postprandial Plasma Citrulline and the Correlation to Intestinal Function Evaluated by 72-Hour Metabolic Balance Studies in Short Bowel Jejunostomy Patients With Intestinal Failure. <i>Journal of Parenteral and Enteral Nutrition</i> , 2018, 42, 418-426.	1.3	10
38	Serum carotenoids and macular pigment optical density in patients with intestinal resections and healthy subjects: an exploratory study. <i>Journal of Nutritional Science</i> , 2018, 7, e8.	0.7	2
39	Nutritional Therapy in Adult Short Bowel Syndrome Patients with Chronic Intestinal Failure. <i>Gastroenterology Clinics of North America</i> , 2018, 47, 61-75.	1.0	13
40	Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. <i>Gastroenterology</i> , 2018, 154, 874-885.	0.6	92
41	Catheter-related bloodstream infections in patients with intestinal failure receiving home parenteral support: risks related to a catheter-salvage strategy. <i>American Journal of Clinical Nutrition</i> , 2018, 107, 743-753.	2.2	26
42	Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice. <i>Physiology and Behavior</i> , 2018, 192, 72-81.	1.0	30
43	Glucagon like peptide-2 and neoplasia; a systematic review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 257-264.	1.4	28
44	Reply to AL Buchman. <i>American Journal of Clinical Nutrition</i> , 2018, 108, 1155-1156.	2.2	0
45	Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1267-1277.	0.9	15
46	Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 410-422.	1.9	45
47	Single-Center, Adult Chronic Intestinal Failure Cohort Analyzed According to the ESPEN-Endorsed Recommendations, Definitions, and Classifications. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 566-574.	1.3	28
48	Home Parenteral Nutrition in Adult Patients With Chronic Intestinal Failure: The Evolution Over 4 Decades in a Tertiary Referral Center. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 1178-1187.	1.3	55
49	The endogenous preproglucagon system is not essential for gut growth homeostasis in mice. <i>Molecular Metabolism</i> , 2017, 6, 681-692.	3.0	31
50	The use of metabolic balance studies in the objective discrimination between intestinal insufficiency and intestinal failure. <i>American Journal of Clinical Nutrition</i> , 2017, 106, ajcn158386.	2.2	7
51	Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 839-848.	2.2	53
52	Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 946-951.	1.3	62
53	European Society of Coloproctology consensus on the surgical management of intestinal failure in adults. <i>Colorectal Disease</i> , 2016, 18, 535-548.	0.7	44
54	Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e142.	1.3	155

#	ARTICLE	IF	CITATIONS
55	ESPEN guidelines on chronic intestinal failure in adults. <i>Clinical Nutrition</i> , 2016, 35, 247-307.	2.3	554
56	Clinical nutrition in the hepatogastroenterology curriculum. <i>World Journal of Gastroenterology</i> , 2016, 22, 1729.	1.4	3
57	Short Bowel Syndrome: Pharmacological Improvement of Bowel Function and Adaptation. , 2016, , 79-96.		0
58	Low-Fat, High-Carbohydrate Parenteral Nutrition (PN) May Potentially Reverse Liver Disease in Long-Term PN-Dependent Infants. <i>Digestive Diseases and Sciences</i> , 2015, 60, 252-259.	1.1	20
59	Gut hormones in the treatment of short-bowel syndrome and intestinal failure. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 14-20.	1.2	60
60	ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. <i>Clinical Nutrition</i> , 2015, 34, 171-180.	2.3	473
61	Use of Teduglutide to Reduce Parenteral Support in Short Bowel Syndrome. , 2015, , 1913-1927.		0
62	Understanding incretins. <i>Intensive Care Medicine</i> , 2014, 40, 1751-1754.	3.9	5
63	New approaches to the treatments of short bowel syndrome-associated intestinal failure. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 182-188.	1.0	32
64	Acute Effects of the Glucagon-Like Peptide 2 Analogue, Teduglutide, on Intestinal Adaptation in Short Bowel Syndrome. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2014, 58, 694-702.	0.9	36
65	Pharmacologic Options for Intestinal Rehabilitation in Patients With Short Bowel Syndrome. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014, 38, 45S-52S.	1.3	55
66	Bovine Colostrum to Children With Short Bowel Syndrome. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014, 38, 99-106.	1.3	32
67	Su2095 Survival and Cause-Specific Mortality in an Intestinal Failure Cohort Depending on Home Parenteral Nutrition (HPN) in a Referral Centre From 1970 to 2010. <i>Gastroenterology</i> , 2014, 146, S-544-S-545.	0.6	1
68	Spectrum of Short Bowel Syndrome in Adults. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014, 38, 8S-13S.	1.3	130
69	Short Bowel Syndrome in Adults. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014, 38, 60S-64S.	1.3	47
70	Use of Teduglutide to Reduce Parenteral Support in Short Bowel Syndrome. , 2014, , 1-17.		0
71	Short bowel syndrome "characterisation of an orphan condition with many phenotypes. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 515-525.	0.5	27
72	The non-surgical treatment of adult patients with short bowel syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 527-538.	0.5	9

#	ARTICLE	IF	CITATIONS
73	Glucagon-like peptide-2 stimulates mucosal microcirculation measured by laser Doppler flowmetry in end-jejunosomy short bowel syndrome patients. <i>Regulatory Peptides</i> , 2013, 180, 12-16.	1.9	24
74	Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL [®] , [©]) scale. <i>Clinical Nutrition</i> , 2013, 32, 789-796.	2.3	45
75	940 Complete Enteral Autonomy and Independence From Parenteral Nutrition/Intravenous Support in Short Bowel Syndrome With Intestinal Failure - Accruing Experience With Teduglutide. <i>Gastroenterology</i> , 2013, 144, S-169.	0.6	5
76	Mo2121 Catheter-Related Bloodstream Infections (CRBSIs) in Adults Intestinal Failure (IF) Patients Depending on Home Parenteral Nutrition (HPN) in a Referral Centre. <i>Gastroenterology</i> , 2013, 144, S-748.	0.6	2
77	Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide – Analyses from a randomised, placebo-controlled study. <i>Clinical Nutrition</i> , 2013, 32, 713-721.	2.3	80
78	Safety and Efficacy of Teduglutide After 52 Weeks of Treatment in Patients With Short Bowel Intestinal Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 815-823.e3.	2.4	135
79	Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure. <i>Regulatory Peptides</i> , 2013, 181, 4-8.	1.9	28
80	A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients. <i>Regulatory Peptides</i> , 2013, 184, 47-53.	1.9	7
81	The novel use of peptide analogs in short bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 197-199.	1.4	3
82	Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. <i>Regulatory Peptides</i> , 2013, 184, 30-39.	1.9	69
83	Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G277-G285.	1.6	48
84	Modern treatment of short bowel syndrome. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2013, 16, 1.	1.3	16
85	Treatment of adult short bowel syndrome patients with teduglutide. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 235-243.	0.9	19
86	Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 159-171.	1.4	81
87	Randomised controlled trial of colostrum to improve intestinal function in patients with short bowel syndrome. <i>European Journal of Clinical Nutrition</i> , 2012, 66, 1059-1065.	1.3	29
88	Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal Failure. <i>Gastroenterology</i> , 2012, 143, 1473-1481.e3.	0.6	378
89	Mo1179 The Evolution of Treatment of Patients With Intestinal Failure With Home Parenteral Nutrition. <i>Gastroenterology</i> , 2012, 142, S-613-S-614.	0.6	5
90	Etiology and Epidemiology of Catheter Related Bloodstream Infections in Patients Receiving Home Parenteral Nutrition in a Gastromedical Center at a Tertiary Hospital in Denmark. <i>Open Microbiology Journal</i> , 2012, 6, 98-101.	0.2	13

#	ARTICLE	IF	CITATIONS
91	The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunosomy short bowel patients. <i>Regulatory Peptides</i> , 2011, 168, 32-38.	1.9	77
92	Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily. <i>Leukemia and Lymphoma</i> , 2011, 52, 400-408.	0.6	15
93	Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. <i>Gut</i> , 2011, 60, 902-914.	6.1	345
94	ESPEN Guidelines on Parenteral Nutrition: Home Parenteral Nutrition (HPN) in adult patients. <i>Clinical Nutrition</i> , 2009, 28, 467-479.	2.3	365
95	ESPEN Guidelines on Parenteral Nutrition: Gastroenterology. <i>Clinical Nutrition</i> , 2009, 28, 415-427.	2.3	119
96	Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1304-1310.	0.6	39
97	Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 929-937.	0.6	32
98	Quality of Life in Diffuse Large B-Cell Lymphoma Patients Treated with CHOP-14 Based Chemotherapy Is Only Affected Temporarily. <i>Blood</i> , 2008, 112, 2384-2384.	0.6	0
99	Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 814-820.	0.6	37
100	Pharmacokinetics of trefoil peptides and their stability in gastrointestinal contents. <i>Peptides</i> , 2007, 28, 1197-1206.	1.2	30
101	Growth Factors in Short-Bowel Syndrome Patients. <i>Gastroenterology Clinics of North America</i> , 2007, 36, 109-121.	1.0	21
102	Home parenteral nutrition in Denmark in the period from 1996 to 2001. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 401-407.	0.6	74
103	Glucagon-Like Peptide-2: Update of the Recent Clinical Trials. <i>Gastroenterology</i> , 2006, 130, S127-S131.	0.6	44
104	The Use of Hormonal Growth Factors in the Treatment of Patients with Short-Bowel Syndrome. <i>Drugs</i> , 2006, 66, 581-589.	4.9	12
105	Short Bowel Syndrome and Intestinal Failure: Consensus Definitions and Overview. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 6-10.	2.4	440
106	Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. <i>Gut</i> , 2005, 54, 1224-1231.	6.1	403
107	Experimental approaches: dietary and hormone therapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 1041-1054.	1.0	19
108	Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. <i>Gut</i> , 2003, 52, 653-658.	6.1	63

#	ARTICLE	IF	CITATIONS
109	Intestinal insufficiency and failure. Danish Medical Bulletin, 2003, 50, 238-61.	0.1	2
110	Short-term Administration of Glucagon-like Peptide-2. Effects on Bone Mineral Density and Markers of Bone Turnover in Short-Bowel Patients with No Colon. Scandinavian Journal of Gastroenterology, 2002, 37, 392-398.	0.6	91
111	The truncated metabolite GLP-2 (3â€³33) interacts with the GLP-2 receptor as a partial agonist. Regulatory Peptides, 2002, 103, 9-15.	1.9	73
112	Enhancing bowel adaptation in short bowel syndrome. Current Gastroenterology Reports, 2002, 4, 338-347.	1.1	44
113	Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology, 2001, 120, 806-815.	0.6	490
114	Effect of High-Dose Growth Hormone and Glutamine on Body Composition, Urine Creatinine Excretion, Fatty Acid Absorption, and Essential Fatty Acids Status in Short Bowel Patients. A Randomized, Double-blind, Crossover, Placebo-controlled Study. Scandinavian Journal of Gastroenterology, 2001, 36, 48-54.	0.6	63
115	Reply to M Esteve-Comas and MA Gassull. American Journal of Clinical Nutrition, 2001, 73, 662.	2.2	1
116	Intestinal growth adaptation and glucagon-like peptide 2 in rats with ileal-jejunal transposition or small bowel resection. Digestive Diseases and Sciences, 2001, 46, 379-388.	1.1	57
117	Deficiencies of essential fatty acids, vitamin A and E and changes in plasma lipoproteins in patients with reduced fat absorption or intestinal failure. European Journal of Clinical Nutrition, 2000, 54, 632-642.	1.3	51
118	Reply to KC McCowen, PR Ling, and BR Bistran. American Journal of Clinical Nutrition, 2000, 71, 1008-1009.	2.2	3
119	In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2884-2888.	1.8	126
120	Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut, 2000, 47, 370-376.	6.1	176
121	Intestinal failure defined by measurements of intestinal energy and wet weight absorption. Gut, 2000, 46, 701-706.	6.1	141
122	Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut, 2000, 47, 199-205.	6.1	173
123	Absorption of calcium and magnesium in patients with intestinal resections treated with medium chain fatty acids. Gut, 2000, 46, 819-823.	6.1	23
124	Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected 125I-GLP-2. Peptides, 2000, 21, 1511-1517.	1.2	33
125	In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2884-2888.	1.8	124
126	Plasma phospholipid fatty acid pattern in severe liver disease. Journal of Hepatology, 2000, 32, 481-487.	1.8	25

#	ARTICLE	IF	CITATIONS
127	Differences in essential fatty acid requirements by enteral and parenteral routes of administration in patients with fat malabsorption. <i>American Journal of Clinical Nutrition</i> , 1999, 70, 78-84.	2.2	37
128	Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. <i>Gut</i> , 1999, 45, 559-563.	6.1	149
129	Colonic Digestion and Absorption of Energy From Carbohydrates and Medium-Chain Fat in Small Bowel Failure. <i>Journal of Parenteral and Enteral Nutrition</i> , 1999, 23, S101-5.	1.3	77
130	Quality of life in patients receiving home parenteral nutrition. <i>Gut</i> , 1999, 44, 844-852.	6.1	189
131	Bile Acid Replacement Therapy with Cholylsarcosine for Short-Bowel Syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 1999, 34, 818-823.	0.6	64
132	Human Rectal Absorption of Short- and Medium-chain C2-C10 Fatty Acids. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 590-594.	0.6	12
133	Adult Patients Receiving Home Parenteral Nutrition in Denmark from 1991 to 1996: Who Will Benefit from Intestinal Transplantation?. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 839-846.	0.6	54
134	The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection. <i>Gut</i> , 1998, 43, 478-483.	6.1	192
135	Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. <i>Gut</i> , 1998, 43, 763-769.	6.1	142
136	Essential fatty acid deficiency in patients receiving home parenteral nutrition. <i>American Journal of Clinical Nutrition</i> , 1998, 68, 126-133.	2.2	71
137	Essential fatty acid deficiency in patients with severe fat malabsorption. <i>American Journal of Clinical Nutrition</i> , 1997, 65, 837-843.	2.2	67
138	Butyrate absorption and lactate secretion in ulcerative colitis. <i>Diseases of the Colon and Rectum</i> , 1995, 38, 519-525.	0.7	25